Skip to main content
. 2024 Nov 12;4(1):100369. doi: 10.1016/j.jacig.2024.100369

Fig 1.

Fig 1

Forrest plots of ORs of comparisons among biologic classes for each outcome under longitudinal repeated-measure models. A, Comparison of anti–IL-4Ra therapy to anti-IgE therapy for each outcome of exacerbations, daily OCS use, and antifungal use. B, Comparison of anti–IL-4Ra to anti–IL-5/IL-5Ra therapies for each outcome. C, Comparison of anti–IL-5/IL-5Ra therapies to anti-IgE therapy for each outcome. Green dots represent the OR estimates of the comparison, and the error bars represent 95% CI.